Mensa J, Barberán J, Soriano A, Llinares P, Marco F, Cantón R, Bou G, González Del Castillo J, Maseda E, Azanza J R, Pasquau J, García-Vidal C, Reguera J M, Sousa D, Gómez J, Montejo M, Borges M, Torres A, Alvarez-Lerma F, Salavert M, Zaragoza R, Oliver A
José Mensa, Servicio de Enfermedades Infecciosas, Hospital Clinic, Barcelona, Spain. jmensa@clinic.
Rev Esp Quimioter. 2018 Feb;31(1):78-100. Epub 2018 Feb 23.
Pseudomonas aeruginosa is characterized by a notable intrinsic resistance to antibiotics, mainly mediated by the expression of inducible chromosomic β-lactamases and the production of constitutive or inducible efflux pumps. Apart from this intrinsic resistance, P. aeruginosa possess an extraordinary ability to develop resistance to nearly all available antimicrobials through selection of mutations. The progressive increase in resistance rates in P. aeruginosa has led to the emergence of strains which, based on their degree of resistance to common antibiotics, have been defined as multidrug resistant, extended-resistant and panresistant strains. These strains are increasingly disseminated worldwide, progressively complicating the treatment of P. aeruginosa infections. In this scenario, the objective of the present guidelines was to review and update published evidence for the treatment of patients with acute, invasive and severe infections caused by P. aeruginosa. To this end, mechanisms of intrinsic resistance, factors favoring development of resistance during antibiotic exposure, prevalence of resistance in Spain, classical and recently appeared new antibiotics active against P. aeruginosa, pharmacodynamic principles predicting efficacy, clinical experience with monotherapy and combination therapy, and principles for antibiotic treatment were reviewed to elaborate recommendations by the panel of experts for empirical and directed treatment of P. aeruginosa invasive infections.
铜绿假单胞菌的特点是对抗生素具有显著的固有耐药性,主要由可诱导的染色体β-内酰胺酶的表达以及组成型或可诱导的外排泵的产生介导。除了这种固有耐药性外,铜绿假单胞菌还具有通过选择突变对几乎所有可用抗菌药物产生耐药性的非凡能力。铜绿假单胞菌耐药率的逐步上升导致了一些菌株的出现,根据它们对常用抗生素的耐药程度,这些菌株被定义为多重耐药、广泛耐药和全耐药菌株。这些菌株在全球范围内越来越多地传播,使铜绿假单胞菌感染的治疗日益复杂化。在这种情况下,本指南的目的是回顾和更新已发表的关于治疗由铜绿假单胞菌引起的急性、侵袭性和严重感染患者的证据。为此,回顾了固有耐药机制、抗生素暴露期间有利于耐药性发展的因素、西班牙的耐药率、对铜绿假单胞菌有活性的经典和最近出现的新型抗生素、预测疗效的药效学原理、单药治疗和联合治疗的临床经验以及抗生素治疗原则,以由专家小组制定关于铜绿假单胞菌侵袭性感染的经验性和针对性治疗的建议。